Literature DB >> 24279471

Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.

Zhao-Shi Bao1, Ming-Yang Li, Jia-Yin Wang, Chuan-Bao Zhang, Hong-Jun Wang, Wei Yan, Yan-Wei Liu, Wei Zhang, Ling Chen, Tao Jiang.   

Abstract

INTRODUCTION: Gliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality. A 9-gene signature was identified as a novel prognostic model reflecting survival situation obviously in gliomas. AIMS: To identify an mRNA expression signature to improve outcome prediction for patients with different glioma grades.
RESULTS: We used whole-genome mRNA expression microarray data of 220 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as a discovery set and data from Rembrandt and GSE16011 for validation sets. Data from every single grade were analyzed by the Kaplan-Meier method with a two-sided log-rank test. Univariate Cox regression and linear risk score formula were applied to derive a gene signature with better prognostic performance. We found that patients who had high risk score according to the signature had poor overall survival compared with patients who had low risk score. Highly expressed genes in the high-risk group were analyzed by gene ontology (GO) and gene set variation analysis (GSVA). As a result, the reason for the divisibility of gliomas was likely due to cell life processes and adhesion.
CONCLUSION: This 9-gene-signature prediction model provided a more accurate predictor of prognosis that denoted patients with high risk score have poor outcome. Moreover, these risk models based on defined molecular profiles showed the considerable prospect in personalized cancer management.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Biomarker; Gliomas; Prognosis; Risk score; mRNA

Mesh:

Substances:

Year:  2013        PMID: 24279471      PMCID: PMC6493176          DOI: 10.1111/cns.12171

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  37 in total

1.  Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.

Authors:  J D Luketich; D M Friedman; T L Weigel; M A Meehan; R J Keenan; D W Townsend; C C Meltzer
Journal:  Ann Thorac Surg       Date:  1999-10       Impact factor: 4.330

2.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  Transcription enhancer factor 1 binds multiple muscle MEF2 and A/T-rich elements during fast-to-slow skeletal muscle fiber type transitions.

Authors:  Natalia Karasseva; Gretchen Tsika; Juan Ji; Aijing Zhang; Xiaoqing Mao; Richard Tsika
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

4.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

Authors:  Izidore S Lossos; Debra K Czerwinski; Ash A Alizadeh; Mark A Wechser; Rob Tibshirani; David Botstein; Ronald Levy
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Tead proteins activate the Foxa2 enhancer in the node in cooperation with a second factor.

Authors:  Atsushi Sawada; Yuriko Nishizaki; Hiroko Sato; Yukari Yada; Rika Nakayama; Shinji Yamamoto; Noriyuki Nishioka; Hisato Kondoh; Hiroshi Sasaki
Journal:  Development       Date:  2005-10-05       Impact factor: 6.868

6.  Physical interaction between the MADS box of serum response factor and the TEA/ATTS DNA-binding domain of transcription enhancer factor-1.

Authors:  M Gupta; P Kogut; F J Davis; N S Belaguli; R J Schwartz; M P Gupta
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

Review 7.  Targeted molecular therapy of GBM.

Authors:  Paul S Mischel; Timothy F Cloughesy
Journal:  Brain Pathol       Date:  2003-01       Impact factor: 6.508

8.  Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.

Authors:  A May; E Günter; F Roth; L Gossner; M Stolte; M Vieth; C Ell
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Identification of minimal enhancer elements sufficient for Pax3 expression in neural crest and implication of Tead2 as a regulator of Pax3.

Authors:  Rita C Milewski; Neil C Chi; Jun Li; Christopher Brown; Min Min Lu; Jonathan A Epstein
Journal:  Development       Date:  2004-01-21       Impact factor: 6.868

10.  Molecular cloning and characterization of a novel human putative transmembrane protein homologous to mouse sideroflexin associated with sideroblastic anemia.

Authors:  Huarui Zheng; Chaoneng Ji; Xianqiong Zou; Maoqing Wu; Zhe Jin; Gang Yin; Jixi Li; Congjing Feng; Haipeng Cheng; Shaohua Gu; Yi Xie; Yumin Mao
Journal:  DNA Seq       Date:  2003-10
View more
  48 in total

1.  An immune-related lncRNA signature for patients with anaplastic gliomas.

Authors:  Wen Wang; Zheng Zhao; Fan Yang; Haoyuan Wang; Fan Wu; Tingyu Liang; Xiaoyan Yan; Jiye Li; Qing Lan; Jiangfei Wang; Jizong Zhao
Journal:  J Neurooncol       Date:  2017-11-23       Impact factor: 4.130

2.  Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling.

Authors:  Feng-Fei Lu; Hao-Yuan Wang; Xiao-Zheng He; Ting-Yu Liang; Wen Wang; Hui-Min Hu; Fan Wu; Yan-Wei Liu; Shi-Zhong Zhang
Journal:  J Neurooncol       Date:  2017-07-27       Impact factor: 4.130

3.  Bioinformatic analysis of gene expression and methylation regulation in glioblastoma.

Authors:  Wen Wang; Zheng Zhao; Fan Wu; Haoyuan Wang; Jiangfei Wang; Qing Lan; Jizong Zhao
Journal:  J Neurooncol       Date:  2017-11-22       Impact factor: 4.130

4.  A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.

Authors:  Ruichao Chai; Kenan Zhang; Kuanyu Wang; Guanzhang Li; Ruoyu Huang; Zheng Zhao; Yanwei Liu; Jing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

5.  [Effects of RAB1A on the proliferation, invasion, and metastasis of tongue squamous cell carcinoma cells].

Authors:  Xue-Hui Sun; Xin Fan; Kai-Li Hu; Wen-Ting Hu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

6.  HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.

Authors:  Wen Cheng; Mingyang Li; Jinquan Cai; Kuanyu Wang; Chuanbao Zhang; Zhaoshi Bao; Yanwei Liu; Anhua Wu
Journal:  J Neurooncol       Date:  2015-01-04       Impact factor: 4.130

7.  Identifying prognostic features by bottom-up approach and correlating to drug repositioning.

Authors:  Wei Li; Jian Yu; Baofeng Lian; Han Sun; Jing Li; Menghuan Zhang; Ling Li; Yixue Li; Qian Liu; Lu Xie
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

8.  Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer.

Authors:  Xingyu Chen; Hua Lan; Dong He; Zhanwang Wang; Runshi Xu; Jing Yuan; Mengqing Xiao; Yao Zhang; Lian Gong; Songshu Xiao; Ke Cao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

9.  Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.

Authors:  Qingbin Li; Baoshi Chen; Jinquan Cai; Ying Sun; Guangzhi Wang; Yongli Li; Ruiyan Li; Yan Feng; Bo Han; Jianlong Li; Yu Tian; Liye Yi; Chuanlu Jiang
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

10.  Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC.

Authors:  Wei Xin; Chaoran Zhao; Longyang Jiang; Dongmei Pei; Lin Zhao; Chengpu Zhang
Journal:  Pathol Oncol Res       Date:  2021-03-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.